Please assess the completion status of the following clinical trial:

Trial Title: Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You are an outpatient diagnosed with stable schizophrenia.~* You are a male or female in the age of 18 to 65 years old.~* You are retrospectively judged by investigators, based on clinical interview and impression, to have been stable for at least 4 weeks.~* You must be able to take olanzapine orodispersible in a single daily dose.~* You are treated with conventional oral olanzapine tablet (as monotherapy) for at least 1 month.~Exclusion Criteria:~* You have used olanzapine in the past and are no longer using it because of a bad reaction.~* You have known Human immunodeficiency virus positive (HIV+) status.~* You have known uncorrected, narrow angle glaucoma.~* You have known Leukopenia, (abnormally low white blood cell count).~* You have a serious or uncontrolled illness (for example: liver disease, history of heart disease, or inadequately controlled diabetes.)~* You have Parkinson's disease.~* You are a female patient who is either pregnant or nursing~* You are taking medications that are not allowed in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).